GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Syra Health Corp (NAS:SYRA) » Definitions » Debt-to-EBITDA

Syra Health (Syra Health) Debt-to-EBITDA : -0.06 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Syra Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syra Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.25 Mil. Syra Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Syra Health's annualized EBITDA for the quarter that ended in Dec. 2023 was $-3.90 Mil. Syra Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Syra Health's Debt-to-EBITDA or its related term are showing as below:

SYRA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -49.67   Med: -0.45   Max: -0.09
Current: -0.09

During the past 4 years, the highest Debt-to-EBITDA Ratio of Syra Health was -0.09. The lowest was -49.67. And the median was -0.45.

SYRA's Debt-to-EBITDA is ranked worse than
100% of 424 companies
in the Healthcare Providers & Services industry
Industry Median: 2.645 vs SYRA: -0.09

Syra Health Debt-to-EBITDA Historical Data

The historical data trend for Syra Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syra Health Debt-to-EBITDA Chart

Syra Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
N/A -49.67 -0.45 -0.09

Syra Health Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only -0.40 -0.56 -0.61 -1.41 -0.06

Competitive Comparison of Syra Health's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Syra Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syra Health's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Syra Health's Debt-to-EBITDA falls into.



Syra Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syra Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.248 + 0) / -2.836
=-0.09

Syra Health's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.248 + 0) / -3.896
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Syra Health  (NAS:SYRA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Syra Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Syra Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Syra Health (Syra Health) Business Description

Traded in Other Exchanges
N/A
Address
1119 Keystone Way North, No. 201, Carmel, IN, USA, 46032
Syra Health Corp is a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. The company leverages deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. It strives to offer comprehensive end-to-end solutions in health education services, population health management, behavioral and mental health, healthcare workforce and digital health. The Company has two main forms of revenue - healthcare staffing revenue and medical communication revenue. The majority of revenue is derived from healthcare staffing.
Executives
Sandeep Allam director, officer: President and Chair 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Feroz Syed 10 percent owner 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Deepika Vuppalanchi director, officer: Chief Executive Officer 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Vijayapal Reddy director 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Avutu Reddy director 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Ketan Paranjape director 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Andrew Dahlem director 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Sherron Rogers director 1119 KEYSTONE WAY N., #201, CARMEL IN 46032
Joe D Thomas 10 percent owner 2046 EAST MURRAY-HOLIDAY ROAD, SALT LAKE CITY UT 84117
Sls Group Llc 10 percent owner 6582 S BIG COTTONWOOD CANYON RD. #200, SALT LAKE CITY UT 84121
Priya Prasad officer: CFO and COO 1119 KEYSTONE WAY N., #201, CARMEL IN 46032